Published in Cancer Detection and Prevention 1999; 23(5):397-400.

Short Communication: Role of Serial Tumor Markers in the Surveillance for Recurrence in Endometrial Cancer

Sue S. T. Lo, M.R.C.O.G.,a U. S. Khoo, M.R.C.Path.,b Danny K L. Cheng, F.R.A.C.O.G., a T. Y. Ng, M.R.C.O.G.,a L.C. Wong, F.R.C.O.G.,a and Hextan Y. S. Ngan, F.R.C.O.G.a

Departments of a Obstetrics and Gynecology, and b Pathology, University of Hong Kong

Address all correspondence and reprint requests to: Prof. HYS Ngan, 6/F Professorial Block. 120 Pokfulam Rd.. Queen Mary Hospital, Hong Kong.

ABSTRACT: The aim of this study is to evaluate the usefulness of tumor markers in the follow-up of patients and endometrial cancer. The sera of 23 patients with elevated pretreatment CA125, CA15.3, and CA19.9 were collected at each follow-up visit and analyzed. Eleven patients had normal posttreatment levels and none of them developed recurrence. Twelve patients had one or more increased tumor markers, 7 (58.3%) of them developed recurrence. Among these seven patients, six had CA125 elevated by at least 10-fold and one had elevated CA19.9. The median lead time between elevation of tumor markers and clinical evidence of recurrence was 6 months. Hence posttreatment elevation of CA125 is a useful predictor for recurrence in patients with elevated pretreatment levels.

KEY WORDS: endometrial cancer, recurrence.